

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

HUMAN CCL3L1 (C-6HIS) PROTEIN

货号: 12036

产品全名: 人 CCL3L1 (C-6His) 蛋白

规格: 10/50/100 µg

基因符号 C-C Motif Chemokine 3-Like 1;G0/G1 Switch Regulatory Protein 19-2;LD78-Beta(1-70);PAT 464.2;Small-Inducible Cytokine A3-Like 1;Tonsillar Lymphocyte LD78 Beta Protein;CCL3L1;D17S1718;G0S19-2;SCYA3L1;CCL3L3

目标蛋白: CCL3L1 UNIPROTID: P16619

描述: Recombinant Human C-C Motif Chemokine 3-Like 1 is produced by our Mammalian expression system and the target gene encoding Ala24-Ala93 is expressed with a 6His tag at the C-terminus.

背景: C-C Motif Chemokine 3-Like 1 (CCL3L1) is a secreted protein that belongs to the intercrine beta (chemokine CC) family. CCL3L1 is a ligand for CCR1, CCR3 and CCR5. CCL3L1 binds to several chemokine receptors including chemokine binding protein 2 and chemokine (C-C motif) receptor 5 (CCR5). CCR5 is a co-receptor for HIV, and binding of this protein to CCR5 inhibits HIV entry. The processed form LD78-beta (3-70) shows a 20-fold to 30-fold higher chemotactic activity and is a very potent inhibitor of HIV-1-infection. The copy number of this gene varies among individuals: most individuals have 1-6 copies in the diploid genome, although rare individuals have zero or more than six copies. The human genome reference assembly contains two full copies of the gene (CCL3L3 and CCL3L1) and a partial pseudogene. This record represents the more centromeric full-length gene.

物种/宿主: HEK293 分子量: 8.82 KDa

分子特征: Not available

纯化: Greater than 95% as determined by reducing SDS-PAGE.

Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization.

储存和运输: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010




Figure 1. Greater than 95% as determined by reducing SDS-PAGE.